Nuwellis Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while iShares 20 Plus Year Treasury Bond ETF trades at $77.84 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 21640.9× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 49,263,490). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| NUWE | TLT | |
|---|---|---|
Market Cap | $2.20M | $47.61B |
Volume | 121,544 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $146.65 | $92.06 |
52-Week Low | $0.68 | $77.11 |
Typical Hold Time | 26 Days | 83 Days |
Enterprise Value | -$1.52M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% amid a challenging bond market environment. The technical picture is bearish with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights Treasury yields reaching multi-decade highs, with the fund experiencing significant outflows and declining nearly 50% over five years as rising interest rates pressure long-duration bonds.
The outlook remains pressured by persistent high interest rates and inflation concerns. While current yields above 5% offer income appeal, further rate hikes or prolonged elevated rates could extend the downtrend. Key risks include Federal Reserve policy uncertainty and economic data volatility. Investors should weigh the income potential against continued price depreciation risk in the current macro environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →